News | April 03, 2026
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
Its a major breakthrough for women’s ovarian cancer care in Europe
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated
